Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 18

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 18
---
 book value per share attributable to this offering                 |     | $ |  0.25 |   |     |   |      |
| As adjusted net tangible book value per share as of September 30, 2025, after giving effect 
 to this offering                                                                            |     |   |       |   |     | $ | 0.15 |
| Dilution per share to new investors purchasing shares in this offering                      |     |   |       |   |     | $ | 1.50 |

The number of shares of Common Stock outstanding after this offering as reflected in the table above is based on the actual number of shares outstanding as of September 30, 2025, which was 51,254,789, and does not include, as of that date:

| • |     | 6,494,441 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted exercise 
 price of $5.13 per share;                                                                                       |

| • |     | 11,841,840 shares of Common Stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity 
 Incentive Plan;                                                                                               |

| • |     | 13,385,490 shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted exercise price 
 of $4.57 per share;                                                                                               |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the                                                 
 Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject             
 to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

S-14

To the extent that any of our outstanding options or warrants are exercised, we grant
additional options under our stock option plans or issue additional warrants, or we issue additional shares of Common Stock in the future, there may be further dilution to the new investors.

S-15

PLAN OF DISTRIBUTION We are offering 9,462,423 shares of our Common Stock and Warrants to purchase 9,462,423 shares of our Common Stock for gross proceeds of